Anzeige
Mehr »
Freitag, 22.05.2026 - Börsentäglich über 12.000 News
Nach dem Tungsten-Schock: Startet hier jetzt die nächste große US-Critical-Minerals-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP4F | ISIN: CA7615161030 | Ticker-Symbol: 31R
Frankfurt
21.05.26 | 17:35
0,029 Euro
+375,00 % +0,023
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REVIVE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
REVIVE THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,0090,03121.05.

Aktuelle News zur REVIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRevive Therapeutics Ltd: Revive expands bucillamine defence program focus6
MiRevive Therapeutics Ltd.: Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures351Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future...
► Artikel lesen
11.03.Revive Therapeutics Ltd: Revive Therapeutics advances bucillamine patents26
11.03.Revive Therapeutics Ltd.: Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases448Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11,...
► Artikel lesen
REVIVE THERAPEUTICS Aktie jetzt für 0€ handeln
15.12.25Revive Therapeutics Ltd: Revive Therapeutics primes the pump on Bucillamine11
15.12.25Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study319TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
► Artikel lesen
21.11.25Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study891TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
► Artikel lesen
12.08.25Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement411TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...
► Artikel lesen
31.07.25Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Private Placement and Debt Settlement364TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1